Xemperia SA

New cancer therapies have provided significant survival benefits in breast cancer (BC). Nevertheless, relapses occur in about a quarter of patients and BC remains the first cause of cancer-related death for women. In order to improve survival, it is crucial to prevent relapses by improving adjuvant therapies and follow-up. To date, there is no specific monitoring test to assess whether BC is cured, dormant or progressing after initial treatment. We have been developing an innovative blood-based test for BC monitoring and early detection of relapses. The clinical implications for such tests are potentially huge: it could change the way women monitored following adjuvant therapy, allowing the rapid therapy adaptation in the event of resistant of progressing cancer before becoming symptomatic